Animal models of amyloidosis and tau allow for investigations into the potential contributions of PGRN to AD pathology and suggest that decreased levels of PGRN play a role in Aβ aggregation, increased tau phosphorylation, and complement activation [72,160,161]. This evidence concerns the gene MAPT and amyloidosis.